The latest from Rhevera Medical.

Endologix Announces 36-Month Results of DETOUR2 Study at 2024 VIVA Late-Breaking Clinical Trial Session

Endologix Appoints Graham Phillips as Chief Operating Officer

One-Year Results of the DETOUR2 Trial published in the Journal of Vascular Surgery (JVS)

Endologix to Present at Upcoming LSI US ’24 Emerging Medtech Summit

Endologix Appoints Mike Mathias as Chief Commercial Officer